JP5723381B2 - Orl−1受容体アンタゴニストとしてのスピロピペリジン化合物 - Google Patents

Orl−1受容体アンタゴニストとしてのスピロピペリジン化合物 Download PDF

Info

Publication number
JP5723381B2
JP5723381B2 JP2012538997A JP2012538997A JP5723381B2 JP 5723381 B2 JP5723381 B2 JP 5723381B2 JP 2012538997 A JP2012538997 A JP 2012538997A JP 2012538997 A JP2012538997 A JP 2012538997A JP 5723381 B2 JP5723381 B2 JP 5723381B2
Authority
JP
Japan
Prior art keywords
methyl
mmol
fluoro
pyran
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2012538997A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013510870A5 (https=
JP2013510870A (ja
Inventor
アナ・ベレン・ベニート・コリャド
ヌリア・ディアス・ブエソ
アルマ・マリア・ヒメネス−アグアド
セリア・ラフエンテ・ブランコ
マリア・アンヘレス・マルティネス−グラウ
コンセプシオン・ペドレガル−テルセロ
ミゲル・アンヘル・トレド・エスクリバノ
Original Assignee
イーライ リリー アンド カンパニー
イーライ リリー アンド カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イーライ リリー アンド カンパニー, イーライ リリー アンド カンパニー filed Critical イーライ リリー アンド カンパニー
Publication of JP2013510870A publication Critical patent/JP2013510870A/ja
Publication of JP2013510870A5 publication Critical patent/JP2013510870A5/ja
Application granted granted Critical
Publication of JP5723381B2 publication Critical patent/JP5723381B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/20Spiro-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2012538997A 2009-11-16 2010-11-12 Orl−1受容体アンタゴニストとしてのスピロピペリジン化合物 Active JP5723381B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP09382245 2009-11-16
EP09382245.0 2009-11-16
US29862810P 2010-01-27 2010-01-27
US61/298,628 2010-01-27
PCT/US2010/056449 WO2011060217A1 (en) 2009-11-16 2010-11-12 Spiropiperidine compounds as orl-1 receptor antagonists

Publications (3)

Publication Number Publication Date
JP2013510870A JP2013510870A (ja) 2013-03-28
JP2013510870A5 JP2013510870A5 (https=) 2013-11-21
JP5723381B2 true JP5723381B2 (ja) 2015-05-27

Family

ID=41800752

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012538997A Active JP5723381B2 (ja) 2009-11-16 2010-11-12 Orl−1受容体アンタゴニストとしてのスピロピペリジン化合物

Country Status (18)

Country Link
US (1) US20120214784A1 (https=)
EP (1) EP2501704B1 (https=)
JP (1) JP5723381B2 (https=)
KR (1) KR101368130B1 (https=)
CN (1) CN102666550B (https=)
AU (1) AU2010319400B2 (https=)
BR (1) BR112012011710A2 (https=)
CA (1) CA2781041C (https=)
DK (1) DK2501704T3 (https=)
EA (1) EA020391B1 (https=)
ES (1) ES2436241T3 (https=)
HR (1) HRP20130969T1 (https=)
MX (1) MX2012005690A (https=)
PL (1) PL2501704T3 (https=)
PT (1) PT2501704E (https=)
RS (1) RS53017B (https=)
SI (1) SI2501704T1 (https=)
WO (1) WO2011060217A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106883246B (zh) * 2009-12-04 2020-05-29 桑诺维恩药品公司 多环化合物及其使用方法
TWI582096B (zh) * 2011-12-06 2017-05-11 美國禮來大藥廠 用於酒精依賴及濫用處理之4',5'-二氫螺[哌啶-4,7'-噻吩并[2,3-c]哌喃]化合物
TW201416370A (zh) 2012-07-31 2014-05-01 Lilly Co Eli 用於治療焦慮之orl-1受體拮抗劑
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
JO3638B1 (ar) * 2015-09-09 2020-08-27 Lilly Co Eli مركبات مفيدة في تثبيط ror - جاما- t
CA3032141A1 (en) 2016-07-29 2018-02-01 Vadim ALEXANDROV Compounds and compositions and uses thereof
UA125519C2 (uk) 2016-07-29 2022-04-13 Суновіон Фармасьютікалз Інк. Сполуки і композиції і їх застосування
KR20190037305A (ko) 2016-08-10 2019-04-05 바이엘 크롭사이언스 악티엔게젤샤프트 해충 방제제로서의 치환된 2-헤테로시클릴 이미다졸릴-카르복스아미드
IL268694B2 (en) 2017-02-16 2023-10-01 Sunovion Pharmaceuticals Inc Treatment of schizophrenia
DK3589637T3 (da) * 2017-03-02 2021-06-14 Lilly Co Eli Forbindelser, der er anvendelige til inhibering af ROR-GAMMA-T
PL3589638T3 (pl) 2017-03-02 2021-09-27 Eli Lilly And Company Związki użyteczne do hamowania ror-gamma-t
BR112020001433A2 (pt) 2017-08-02 2020-07-28 Sunovion Pharmaceuticals Inc. compostos de isocromano e usos dos mesmos
EA202091945A1 (ru) 2018-02-16 2021-01-18 Суновион Фармасьютикалз Инк. Соли, кристаллические формы и способы их получения
TWI848031B (zh) 2018-12-17 2024-07-11 美商維泰克斯製藥公司 Apol1抑制劑及其使用方法
MX2021010880A (es) 2019-03-14 2022-01-18 Sunovion Pharmaceuticals Inc Sales de un compuesto de isocromanilo y formas cristalinas, procesos de preparacion, usos terapeuticos y composiciones farmaceuticas de las mismas.
EP3766879A1 (en) 2019-07-19 2021-01-20 Basf Se Pesticidal pyrazole derivatives
CN115734785A (zh) 2020-04-14 2023-03-03 桑诺维恩药品公司 (S)-(4,5-二氢-7H-噻吩并[2,3-c]吡喃-7-基)-N-甲基甲胺用于治疗神经和精神方面的病症
WO2021252863A1 (en) 2020-06-12 2021-12-16 Vertex Pharmaceuticals Incorporated Solid forms of apol1 inhibitor and using the same
IL300298B2 (en) 2020-08-26 2025-06-01 Vertex Pharma Inhibitors of apol1 and methods of using same
CN119343353A (zh) * 2022-02-08 2025-01-21 弗特克斯药品有限公司 作为APOL1抑制剂的2-甲基-4',5'-二氢螺[哌啶-4,7'-噻吩并[2,3-c]吡喃]衍生物和其使用方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003235912A1 (en) 2002-05-10 2003-11-11 Taisho Pharmaceutical Co., Ltd. Spiro-ring compound
WO2005016913A1 (en) 2003-08-19 2005-02-24 Pfizer Japan, Inc. Tetrahydroisoquinoline or isochroman compounds as orl-1 receptor ligands for the treatment of pain and cns disorders
DE10360792A1 (de) * 2003-12-23 2005-07-28 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
CA2563164A1 (en) * 2004-03-29 2005-10-06 Pfizer Inc. Alpha aryl or heteroaryl methyl beta piperidino propanoic acid compounds as orl1-receptor antagonists
DE102004039382A1 (de) * 2004-08-13 2006-02-23 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
US7655670B2 (en) * 2005-06-02 2010-02-02 Janssen Pharmaceutica N.V. 3-spirocyclic indolyl derivatives useful as ORL-1 receptor modulators

Also Published As

Publication number Publication date
EA020391B1 (ru) 2014-10-30
DK2501704T3 (da) 2013-10-14
EA201290355A1 (ru) 2012-10-30
AU2010319400A1 (en) 2012-06-07
CA2781041C (en) 2015-01-06
KR101368130B1 (ko) 2014-02-27
CA2781041A1 (en) 2011-05-19
CN102666550A (zh) 2012-09-12
PL2501704T3 (pl) 2014-02-28
ES2436241T3 (es) 2013-12-27
MX2012005690A (es) 2012-06-13
PT2501704E (pt) 2013-12-05
WO2011060217A1 (en) 2011-05-19
EP2501704A1 (en) 2012-09-26
US20120214784A1 (en) 2012-08-23
SI2501704T1 (sl) 2013-11-29
RS53017B (sr) 2014-04-30
AU2010319400B2 (en) 2013-12-19
HRP20130969T1 (hr) 2013-11-22
EP2501704B1 (en) 2013-09-18
CN102666550B (zh) 2015-07-15
KR20120082927A (ko) 2012-07-24
JP2013510870A (ja) 2013-03-28
BR112012011710A2 (pt) 2016-03-01

Similar Documents

Publication Publication Date Title
JP5723381B2 (ja) Orl−1受容体アンタゴニストとしてのスピロピペリジン化合物
JP5680101B2 (ja) Orl−1受容体アンタゴニストとしてのスピロピペリジン化合物
US20240417407A1 (en) Furoindazole derivatives as gpr84 antagonists
KR20180073638A (ko) 통증에 대해 활성을 갖는 옥사-디아자스피로 화합물들
HK1169988B (en) Spiropiperidine compounds as orl-1 receptor antagonists
TW200524608A (en) Therapeutic agents
BR112012012150A2 (pt) compostos spiro piperidina como antagonistas de recep-tor orl-1

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131004

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20131004

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140930

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20141002

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141222

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150317

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150327

R150 Certificate of patent or registration of utility model

Ref document number: 5723381

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250